Learning Objectives
Many types of genetic engineering have yielded clear benefits with few apparent risks. Few would question, for example, the value of our now abundant supply of human insulin produced by genetically engineered bacteria. However, many emerging applications of genetic engineering are much more controversial, often because their potential benefits are pitted against significant risks, real or perceived. This is certainly the case for gene therapy, a clinical application of genetic engineering that may one day provide a cure for many diseases but is still largely an experimental approach to treatment.
Human diseases that result from genetic mutations are often difficult to treat with drugs or other traditional forms of therapy because the signs and symptoms of disease result from abnormalities in a patients genome. For example, a patient may have a genetic mutation that prevents the expression of a specific protein required for the normal function of a particular cell type. This is the case in patients with Severe Combined Immunodeficiency (SCID), a genetic disease that impairs the function of certain white blood cells essential to the immune system.
Gene therapy attempts to correct genetic abnormalities by introducing a nonmutated, functional gene into the patients genome. The nonmutated gene encodes a functional protein that the patient would otherwise be unable to produce. Viral vectors such as adenovirus are sometimes used to introduce the functional gene; part of the viral genome is removed and replaced with the desired gene (Figure1). More advanced forms of gene therapy attempt to correct the mutation at the original site in the genome, such as is the case with treatment of SCID.
Figure1. Gene therapy using an adenovirus vector can be used to treat or cure certain genetic diseases in which a patient has a defective gene. (credit: modification of work by National Institutes of Health)
So far, gene therapies have proven relatively ineffective, with the possible exceptions of treatments for cystic fibrosis and adenosine deaminase deficiency, a type of SCID. Other trials have shown the clear hazards of attempting genetic manipulation in complex multicellular organisms like humans. In some patients, the use of an adenovirus vector can trigger an unanticipated inflammatory response from the immune system, which may lead to organ failure. Moreover, because viruses can often target multiple cell types, the virus vector may infect cells not targeted for the therapy, damaging these other cells and possibly leading to illnesses such as cancer. Another potential risk is that the modified virus could revert to being infectious and cause disease in the patient. Lastly, there is a risk that the inserted gene could unintentionally inactivate another important gene in the patients genome, disrupting normal cell cycling and possibly leading to tumor formation and cancer. Because gene therapy involves so many risks, candidates for gene therapy need to be fully informed of these risks before providing informed consent to undergo the therapy.
The risks of gene therapy were realized in the 1999 case of Jesse Gelsinger, an 18-year-old patient who received gene therapy as part of a clinical trial at the University of Pennsylvania. Jesse received gene therapy for a condition called ornithine transcarbamylase (OTC) deficiency, which leads to ammonia accumulation in the blood due to deficient ammonia processing. Four days after the treatment, Jesse died after a massive immune response to the adenovirus vector.
Until that point, researchers had not really considered an immune response to the vector to be a legitimate risk, but on investigation, it appears that the researchers had some evidence suggesting that this was a possible outcome. Prior to Jesses treatment, several other human patients had suffered side effects of the treatment, and three monkeys used in a trial had died as a result of inflammation and clotting disorders. Despite this information, it appears that neither Jesse nor his family were made aware of these outcomes when they consented to the therapy. Jesses death was the first patient death due to a gene therapy treatment and resulted in the immediate halting of the clinical trial in which he was involved, the subsequent halting of all other gene therapy trials at the University of Pennsylvania, and the investigation of all other gene therapy trials in the United States. As a result, the regulation and oversight of gene therapy overall was reexamined, resulting in new regulatory protocols that are still in place today.
Presently, there is significant oversight of gene therapy clinical trials. At the federal level, three agencies regulate gene therapy in parallel: the Food and Drug Administration (FDA), the Office of Human Research Protection (OHRP), and the Recombinant DNA Advisory Committee (RAC) at the National Institutes of Health (NIH). Along with several local agencies, these federal agencies interact with the institutional review board to ensure that protocols are in place to protect patient safety during clinical trials. Compliance with these protocols is enforced mostly on the local level in cooperation with the federal agencies. Gene therapies are currently under the most extensive federal and local review compared to other types of therapies, which are more typically only under the review of the FDA. Some researchers believe that these extensive regulations actually inhibit progress in gene therapy research. In 2013, the Institute of Medicine (now the National Academy of Medicine) called upon the NIH to relax its review of gene therapy trials in most cases. However, ensuring patient safety continues to be of utmost concern.
Beyond the health risks of gene therapy, the ability to genetically modify humans poses a number of ethical issues related to the limits of such therapy. While current research is focused on gene therapy for genetic diseases, scientists might one day apply these methods to manipulate other genetic traits not perceived as desirable. This raises questions such as:
The ability to alter reproductive cells using gene therapy could also generate new ethical dilemmas. To date, the various types of gene therapies have been targeted to somatic cells, the non-reproductive cells within the body. Because somatic cell traits are not inherited, any genetic changes accomplished by somatic-cell gene therapy would not be passed on to offspring. However, should scientists successfully introduce new genes to germ cells (eggs or sperm), the resulting traits could be passed on to offspring. This approach, called germ-line gene therapy, could potentially be used to combat heritable diseases, but it could also lead to unintended consequences for future generations. Moreover, there is the question of informed consent, because those impacted by germ-line gene therapy are unborn and therefore unable to choose whether they receive the therapy. For these reasons, the U.S. government does not currently fund research projects investigating germ-line gene therapies in humans.
While there are currently no gene therapies on the market in the United States, many are in the pipeline and it is likely that some will eventually be approved. With recent advances in gene therapies targeting p53, a gene whose somatic cell mutations have been implicated in over 50% of human cancers, cancer treatments through gene therapies could become much more widespread once they reach the commercial market.
Bringing any new therapy to market poses ethical questions that pit the expected benefits against the risks. How quickly should new therapies be brought to the market? How can we ensure that new therapies have been sufficiently tested for safety and effectiveness before they are marketed to the public? The process by which new therapies are developed and approved complicates such questions, as those involved in the approval process are often under significant pressure to get a new therapy approved even in the face of significant risks.
To receive FDA approval for a new therapy, researchers must collect significant laboratory data from animal trials and submit an Investigational New Drug (IND) application to the FDAs Center for Drug Evaluation and Research (CDER). Following a 30-day waiting period during which the FDA reviews the IND, clinical trials involving human subjects may begin. If the FDA perceives a problem prior to or during the clinical trial, the FDA can order a clinical hold until any problems are addressed. During clinical trials, researchers collect and analyze data on the therapys effectiveness and safety, including any side effects observed. Once the therapy meets FDA standards for effectiveness and safety, the developers can submit a New Drug Application (NDA) that details how the therapy will be manufactured, packaged, monitored, and administered.
Because new gene therapies are frequently the result of many years (even decades) of laboratory and clinical research, they require a significant financial investment. By the time a therapy has reached the clinical trials stage, the financial stakes are high for pharmaceutical companies and their shareholders. This creates potential conflicts of interest that can sometimes affect the objective judgment of researchers, their funders, and even trial participants. The Jesse Gelsinger case (see Gene Therapy Gone Wrong above) is a classic example. Faced with a life-threatening disease and no reasonable treatments available, it is easy to see why a patient might be eager to participate in a clinical trial no matter the risks. It is also easy to see how a researcher might view the short-term risks for a small group of study participants as a small price to pay for the potential benefits of a game-changing new treatment.
Gelsingers death led to increased scrutiny of gene therapy, and subsequent negative outcomes of gene therapy have resulted in the temporary halting of clinical trials pending further investigation. For example, when children in France treated with gene therapy for SCID began to develop leukemia several years after treatment, the FDA temporarily stopped clinical trials of similar types of gene therapy occurring in the United States. Cases like these highlight the need for researchers and health professionals not only to value human well-being and patients rights over profitability, but also to maintain scientific objectivity when evaluating the risks and benefits of new therapies.
At what point can the FDA halt the development or use of gene therapy?
Answer d. The FDA halt the development or use of gene therapy at any of the points listed above.
_____________ is a common viral vector used in gene therapy for introducing a new gene into a specifically targeted cell type.
Adenovirus is a common viral vector used in gene therapy for introducing a new gene into a specifically targeted cell type.
Excerpt from:
- About the Gene Therapy Review [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Contribute an Article [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- EBSCO Publishing Deal [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Advertising Opportunities [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Instructions for Authors [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Isis Collaboration With Ortho-McNeil Inc for Metabolic Diseases [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Dystrophin Gene Transfer safe in Duchenne muscular dystrophy [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Researchers Identify Gene for Rare Form of Spinal Muscular Atrophy [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Fatal brain cancer tamed by New gene therapy [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Gene therapy effective in fighting obesity in mice [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Genzyme gene therapy for people with peripheral artery disease failed in a clinical trial to help them regain some mobility [Last Updated On: November 8th, 2009] [Originally Added On: November 8th, 2009]
- Gene Therapy May Stall Inherited Emphysema [Last Updated On: December 31st, 2009] [Originally Added On: December 31st, 2009]
- Gene Therapy and Stem Cells Save Limb [Last Updated On: December 31st, 2009] [Originally Added On: December 31st, 2009]
- Faulty Circuits (preview) [Last Updated On: August 17th, 2024] [Originally Added On: April 7th, 2010]
- Rare flowers and common herbal supplements get unmasked with plant DNA barcoding [Last Updated On: August 17th, 2024] [Originally Added On: April 20th, 2010]
- Biomarker Studies Could Realize Goal of More Effective and Personalized Cancer Medicine [Last Updated On: August 17th, 2024] [Originally Added On: April 27th, 2010]
- Schizophrenia shares genetic links with autism, genome study shows [Last Updated On: August 17th, 2024] [Originally Added On: May 12th, 2010]
- Alzheimer's: Forestalling the Darkness with New Approaches (preview) [Last Updated On: August 17th, 2024] [Originally Added On: May 28th, 2010]
- Alzheimer's: Forestalling the Darkness with New Approaches (preview) [Last Updated On: August 17th, 2024] [Originally Added On: May 28th, 2010]
- Large-Scale Autism Study Reveals Disorder's Genetic Complexity [Last Updated On: August 17th, 2024] [Originally Added On: June 12th, 2010]
- Large-Scale Autism Study Reveals Disorder's Genetic Complexity [Last Updated On: August 17th, 2024] [Originally Added On: June 12th, 2010]
- Cancer Therapy Goes Viral: Progress Is Made Tackling Tumors with Viruses [Last Updated On: August 17th, 2024] [Originally Added On: June 24th, 2010]
- Vaccines Derived from Patients' Tumor Cells Are Individualizing Cancer Treatment [Last Updated On: August 17th, 2024] [Originally Added On: June 26th, 2010]
- Vaccines Derived from Patients' Tumor Cells Are Individualizing Cancer Treatment [Last Updated On: August 17th, 2024] [Originally Added On: June 26th, 2010]
- A genome story: 10th anniversary commentary by Francis Collins [Last Updated On: August 17th, 2024] [Originally Added On: June 29th, 2010]
- Hair Trigger: How a Cell's Primary Cilium Functions as a Molecular Antenna [Last Updated On: August 17th, 2024] [Originally Added On: June 30th, 2010]
- Hair Trigger: How a Cell's Primary Cilium Functions as a Molecular Antenna [Last Updated On: August 17th, 2024] [Originally Added On: June 30th, 2010]
- DNA Drugs Come of Age (preview) [Last Updated On: August 17th, 2024] [Originally Added On: July 16th, 2010]
- 2 Genes Linked to Embryonic Brain Impairment in Down's Syndrome [Last Updated On: August 17th, 2024] [Originally Added On: July 22nd, 2010]
- 2 Genes Linked to Embryonic Brain Impairment in Down's Syndrome [Last Updated On: August 17th, 2024] [Originally Added On: July 22nd, 2010]
- Stem Cells from Reprogrammed Adult Cells Found to Bring Along Genetic Defects of Their Donors [Last Updated On: August 17th, 2024] [Originally Added On: October 11th, 2010]
- Was Darwin a Punk? A Q&A with Punker-Paleontologist Greg Graffin [Last Updated On: August 17th, 2024] [Originally Added On: October 11th, 2010]
- Was Darwin a Punk? A Q&A with Punker-Paleontologist Greg Graffin [Last Updated On: August 17th, 2024] [Originally Added On: October 11th, 2010]
- Parkinsonian Power Failure: Neuron Degeneration May Be Caused by a Cellular Energy System Breakdown [Last Updated On: August 17th, 2024] [Originally Added On: October 11th, 2010]
- Desperation Drives Parents to Dubious Autism Treatments (preview) [Last Updated On: August 17th, 2024] [Originally Added On: October 17th, 2010]
- Revolution Postponed: Why the Human Genome Project Has Been Disappointing (preview) [Last Updated On: August 17th, 2024] [Originally Added On: November 7th, 2010]
- Controlling the Brain with Light (preview) [Last Updated On: August 17th, 2024] [Originally Added On: November 7th, 2010]
- Optogenetics: Controlling the Brain with Light [Extended Version] [Last Updated On: August 17th, 2024] [Originally Added On: November 7th, 2010]
- Clear New Insights into the Genetics of Depression [Last Updated On: August 17th, 2024] [Originally Added On: November 7th, 2010]
- TEDMED 2010: Technology and the people [Last Updated On: August 17th, 2024] [Originally Added On: November 7th, 2010]
- Bacteria, the anti-cancer soldier [Last Updated On: August 17th, 2024] [Originally Added On: November 7th, 2010]
- Scientific regress: When science goes backward [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2011]
- Can You Live Forever? Maybe Not--But You Can Have Fun Trying [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2011]
- How to Fix the Obesity Crisis (preview) [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2011]
- Personalizing cancer medicine [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2011]
- New Salmonella strain delivers gene-based therapy to fight virus in mice [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2011]
- Steps toward a Bionic Eye [Last Updated On: August 17th, 2024] [Originally Added On: February 20th, 2011]
- Giving HIV a Poor Reception: New AIDS Treatment Tinkers with Immune Cell Genes [Last Updated On: August 17th, 2024] [Originally Added On: March 6th, 2011]
- Smaller, cheaper, faster: Does Moore's law apply to solar cells? [Last Updated On: August 17th, 2024] [Originally Added On: March 27th, 2011]
- Smaller, cheaper, faster: Does Moore's law apply to solar cells? [Last Updated On: August 17th, 2024] [Originally Added On: March 27th, 2011]
- New Drugs for Hepatitis C on the Horizon [Last Updated On: August 17th, 2024] [Originally Added On: April 10th, 2011]
- Can we capture all of the world's carbon emissions? [Last Updated On: August 17th, 2024] [Originally Added On: April 10th, 2011]
- Can we capture all of the world's carbon emissions? [Last Updated On: August 17th, 2024] [Originally Added On: April 10th, 2011]
- Drug-resistant genes found in cholera and dysentery strains in New Delhi water supply [Last Updated On: August 17th, 2024] [Originally Added On: May 1st, 2011]
- Fast Track to Vaccines: How Systems Biology Speeds Drug Development (preview) [Last Updated On: August 17th, 2024] [Originally Added On: May 1st, 2011]
- TNVitamins.com – $10 Off Of $50 order [Last Updated On: May 7th, 2011] [Originally Added On: May 7th, 2011]
- 15% Off Any PetAlive Order [Last Updated On: May 7th, 2011] [Originally Added On: May 7th, 2011]
- At PetAlive – $10 off order of $50 or more [Last Updated On: May 7th, 2011] [Originally Added On: May 7th, 2011]
- Native Remedies coupon – 5% Off Any Order [Last Updated On: May 7th, 2011] [Originally Added On: May 7th, 2011]
- Native Remedies – Save $5 coupon [Last Updated On: May 7th, 2011] [Originally Added On: May 7th, 2011]
- Welcome to the Gene Therapy Review [Last Updated On: May 15th, 2011] [Originally Added On: May 15th, 2011]
- Editorial Board [Last Updated On: May 15th, 2011] [Originally Added On: May 15th, 2011]
- Gene Therapy Job Board [Last Updated On: May 15th, 2011] [Originally Added On: May 15th, 2011]
- Corporate Membership [Last Updated On: May 22nd, 2011] [Originally Added On: May 22nd, 2011]
- Native Remedies coupon – 25% Off Any Order [Last Updated On: May 29th, 2011] [Originally Added On: May 29th, 2011]
- What is Gene Therapy? [Last Updated On: June 19th, 2011] [Originally Added On: June 19th, 2011]
- Autism's Tangled Genetics Full of Rare and Varied Mutations [Last Updated On: August 17th, 2024] [Originally Added On: June 19th, 2011]
- Autism's Tangled Genetics Full of Rare and Varied Mutations [Last Updated On: August 17th, 2024] [Originally Added On: June 19th, 2011]
- A New Look at Obsessive-Compulsive Disorder (preview) [Last Updated On: August 17th, 2024] [Originally Added On: June 19th, 2011]
- Close Encounters of Science and Medicine [Last Updated On: August 17th, 2024] [Originally Added On: July 3rd, 2011]
- New Report Details Uphill Battle to Solve the U.S.'s Pain Problem [Last Updated On: August 17th, 2024] [Originally Added On: July 24th, 2011]
- New Report Details Uphill Battle to Solve the U.S.'s Pain Problem [Last Updated On: August 17th, 2024] [Originally Added On: July 24th, 2011]
- A Breath of Fresh Air: New Hope for Cystic Fibrosis Treatment (preview) [Last Updated On: August 17th, 2024] [Originally Added On: August 7th, 2011]
- Studying Mental Illness in a Dish [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- The Puzzle of Pancreatic Cancer: How Steve Jobs Did Not Beat the Oddsbut Nobel Winner Ralph Steinman Did [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- The Puzzle of Pancreatic Cancer: How Steve Jobs Did Not Beat the Odds?but Nobel Winner Ralph Steinman Did [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- Did Alternative Medicine Extend or Abbreviate Steve Jobs's Life? [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- Did Alternative Medicine Extend or Abbreviate Steve Jobs's Life? [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- Calendar: MIND Events in November and December [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- He's No Gregory House--Which Is a Good Thing (preview) [Last Updated On: August 17th, 2024] [Originally Added On: November 20th, 2011]